Abigail Sprouse, Registered Nurse - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 619 Church Street, Port Norris, NJ 08349 Phone: 609-501-3832 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that its long term partner, Shire has extended the existing partnership in the rare genetic disease space.
The American Academy of Dermatology Association (Academy) today said that the U.S. Food and Drug Administration's (FDA) new sunscreen regulations will help Americans reduce their risk for skin cancer by guiding them to the most effective sunscreens and advising them on other sun-protection measures.
Cognizant today announced that Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmology applications, has deployed Cognizant MedVantage, a cloud-based integrated complaint handling solution.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.
In Europe alone, more than 25,000 people die each year from infections caused by multi-resistant bacteria. Researchers from University of Copenhagen have now developed and characterized a substance that quickly and effectively kills the virulent bacteria. The substance employs a multifunctional mechanism that reduces the risk of antibiotic resistance. The findings have recently been published in the scientific journal Chemistry & Biology.
› Verified 4 days ago